Sun Pharma to Acquire Organon for $14 Per Share
Catch up on the weekend's top five stories with this list compiled by The Fly: 1) President Trump said on social media: "I just cancelled the trip of my representatives going is Islamabad, Pakistan, to meet with the Iranians. Too much time wasted on traveling, too much work! Besides which, there is tremendous infighting and confusion within their 'leadership.' Nobody knows who is in charge, including them. Also, we have all the cards, they have none! If they want to talk, all they have to do is call!!!" 2) Sun Pharmaceutical Industries and Organon & Co. (OGN) announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75B. Transaction Summary: Sun Pharma will acquire 100% of Organon's issued and outstanding shares for cash. Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction will be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. The transaction is expected to close in early 2027, subject to customary conditions, including regulatory approvals and Organon stockholder approval. The transaction has been approved by the Boards of Directors of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. 3) Oracle's (ORCL) $16B financing for a giant data center in Michigan has finally wrapped after months of negotiations with investors, Davide Barbuscia, Caleb Mutua, and Natalie Wong of Bloomberg reports. Bank of America (BAC) sold $14B of bonds tied to the project. Pimco bought $10B of the bonds that priced Friday, while other investors bought the remaining debt, people with knowledge of the matter told Bloomberg. 4) NeuroSense (NRSN) announced on Friday that Dr. Ferenc Tracik will step down from his role as the company's Chief Medical Officer, effective April 27. Tracik will continue to support the company as an independent advisor, NeuroSense added. "Dr. Tracik's departure is not the result of any disagreement with the Company on matters relating to its operations, policies, or practices," it said. 5) Medtronic (MDT) announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology.
